A Study of TAR-200 in Combination With Cetrelimab and Cetrelimab Alone in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder
Urinary Bladder Neoplasms
2Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2
4 insiders sold shares within a month
Since Aug 17, 2026 · was worth 5, fading over time
Worry score2
Score over time
- Stage
- Phase 2
- Patients
- 163 (final count)
- Started
- Jul 7, 2022
- Main results expected
- Feb 4, 2025
- Fully finished
- Mar 31, 2026
- Results posted
- Feb 17, 2026
What counts as success
The trial's main goal(s), called the “primary outcome.”
Pathologic Complete Response (pCR) Rate
Measured over: At Week 12
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2, since 2026-08-17, fades (half-life)
Raw record changes
- none yet
Trial ID NCT04919512 · record last updated 2026-11-03 · checked 2026-11-09 15:47 UTC